Recent developments in the assessment of efficacy in clinical trials of diabetic neuropathy

Moaz Mojaddidi, Cristian Quattrini, Mitra Tavakoli, Rayaz Malik

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

A large number of measures may be employed in clinical practice and for epidemiologic studies to quantify and risk stratify diabetic patients with neuropathy. However, not all measures are suitable for assessing the benefits of therapeutic intervention. Therefore, for the purpose of this review we focus on measures that may be employed to define the efficacy of interventions in clinical trials of human diabetic neuropathy. Two major types of end points are used: 1) those that assess symptoms for defining efficacy in painful diabetic neuropathy, and 2) those that assess neurologic deficits that assess the effects of treatments that may prevent further degeneration or promote repair.

Original languageEnglish
Pages (from-to)417-422
Number of pages6
JournalCurrent Diabetes Reports
Volume5
Issue number6
DOIs
Publication statusPublished - Dec 2005
Externally publishedYes

Fingerprint

Diabetic Neuropathies
Clinical Trials
Neurologic Manifestations
Epidemiologic Studies
Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Cite this

Recent developments in the assessment of efficacy in clinical trials of diabetic neuropathy. / Mojaddidi, Moaz; Quattrini, Cristian; Tavakoli, Mitra; Malik, Rayaz.

In: Current Diabetes Reports, Vol. 5, No. 6, 12.2005, p. 417-422.

Research output: Contribution to journalReview article

Mojaddidi, Moaz ; Quattrini, Cristian ; Tavakoli, Mitra ; Malik, Rayaz. / Recent developments in the assessment of efficacy in clinical trials of diabetic neuropathy. In: Current Diabetes Reports. 2005 ; Vol. 5, No. 6. pp. 417-422.
@article{c15fca5eb877454089b42b1d164bec9a,
title = "Recent developments in the assessment of efficacy in clinical trials of diabetic neuropathy",
abstract = "A large number of measures may be employed in clinical practice and for epidemiologic studies to quantify and risk stratify diabetic patients with neuropathy. However, not all measures are suitable for assessing the benefits of therapeutic intervention. Therefore, for the purpose of this review we focus on measures that may be employed to define the efficacy of interventions in clinical trials of human diabetic neuropathy. Two major types of end points are used: 1) those that assess symptoms for defining efficacy in painful diabetic neuropathy, and 2) those that assess neurologic deficits that assess the effects of treatments that may prevent further degeneration or promote repair.",
author = "Moaz Mojaddidi and Cristian Quattrini and Mitra Tavakoli and Rayaz Malik",
year = "2005",
month = "12",
doi = "10.1007/s11892-005-0048-6",
language = "English",
volume = "5",
pages = "417--422",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "6",

}

TY - JOUR

T1 - Recent developments in the assessment of efficacy in clinical trials of diabetic neuropathy

AU - Mojaddidi, Moaz

AU - Quattrini, Cristian

AU - Tavakoli, Mitra

AU - Malik, Rayaz

PY - 2005/12

Y1 - 2005/12

N2 - A large number of measures may be employed in clinical practice and for epidemiologic studies to quantify and risk stratify diabetic patients with neuropathy. However, not all measures are suitable for assessing the benefits of therapeutic intervention. Therefore, for the purpose of this review we focus on measures that may be employed to define the efficacy of interventions in clinical trials of human diabetic neuropathy. Two major types of end points are used: 1) those that assess symptoms for defining efficacy in painful diabetic neuropathy, and 2) those that assess neurologic deficits that assess the effects of treatments that may prevent further degeneration or promote repair.

AB - A large number of measures may be employed in clinical practice and for epidemiologic studies to quantify and risk stratify diabetic patients with neuropathy. However, not all measures are suitable for assessing the benefits of therapeutic intervention. Therefore, for the purpose of this review we focus on measures that may be employed to define the efficacy of interventions in clinical trials of human diabetic neuropathy. Two major types of end points are used: 1) those that assess symptoms for defining efficacy in painful diabetic neuropathy, and 2) those that assess neurologic deficits that assess the effects of treatments that may prevent further degeneration or promote repair.

UR - http://www.scopus.com/inward/record.url?scp=29644437913&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29644437913&partnerID=8YFLogxK

U2 - 10.1007/s11892-005-0048-6

DO - 10.1007/s11892-005-0048-6

M3 - Review article

VL - 5

SP - 417

EP - 422

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 6

ER -